Fresh analysis indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Research printed in a leading medical journal shows that while obese individuals frequently drop about a fifth of their body weight while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying such treatments need to be informed of the potential of fast weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
This pace of regain implies a return to original weight in about 18 months.
Analyzing Approaches
The research, which examined 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who shed pounds through dieting typically have a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts propose the mechanism of the injections explains the heightened weight return.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Disease?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, considering the likelihood of weight regain, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
People who have stopped the jabs report a intense return of appetite.
"It felt as if a switch flipping and I was suddenly starving," recalled an individual.
This challenge is worsened if individuals have not developed sustainable dietary or behavioural modifications during treatment.
Significant Use
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated lifestyle changes.